Evidence map›Paper›PMID 28776937›Full record

ArticleMacromolecular bioscience2018

Synthesis and Evaluation of Chloroquine-Containing DMAEMA Copolymers as Efficient Anti-miRNA Delivery Vectors with Improved Endosomal Escape and Antimigratory Activity in Cancer Cells.

Ying Xie, Fei Yu, Weimin Tang, Bolutito Oluwole Alade, Zheng-Hong Peng, Yazhe Wang, Jing Li, David Oupický

Abstract read
In one paragraph

Article in Macromolecular bioscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Quinine copolymer reporters promote efficient intracellular DNA delivery and illuminate a protein-induced unpackaging mechanism.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  9. Promise of chemokine network-targeted nanoparticles in combination nucleic acid therapies of metastatic cancer.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ying XieCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Fei YuCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Weimin TangCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Bolutito Oluwole AladeCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Zheng-Hong PengCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Yazhe WangCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Jing LiCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
David OupickýCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA.ORCID 0000-0003-4710-861X
University of Nebraska Medical Center · US

Funding

Multilayered redox-responsive nanoparticles for delivery of drug-siRNA combinatioR01EB015216 · NIBIB · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OUPICKY, DAVID · 2014 to 2017
$1.3M
Nanoparticles based on histone deacetylase inhibitors for combination treatmentsR21EB019175 · NIBIB · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OUPICKY, DAVID · 2015 to 2016
$430k
Dual-function nanoparticles for oral treatment of inflammatory bowel diseaseR21EB020308 · NIBIB · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OUPICKY, DAVID · 2015 to 2016
$428k
NIBIB NIH HHS R01 EB015216NIBIB NIH HHS R21 EB019175NIBIB NIH HHS R21 EB020308
6 · The paper itself

Abstract

Chloroquine-containing 2-(dimethylamino)ethyl methacrylate copolymers (PDCs) are synthesized by reversible addition-fragmentation chain-transfer polymerization. Systematic evaluation is performed to test the hypothesis that presence of chloroquine (CQ) in the PDC structure will improve miRNA delivery due to enhanced endosomal escape while simultaneously contribute to anticancer activity of PDC/miRNA polyplexes through inhibition of cancer cell migration. The results show that miRNA delivery efficiency is dependent both on the molecular weight and CQ. The best performing PDC/miRNA polyplexes show effective endosomal escape of miRNA. PDC polyplexes with therapeutic miR-210 show promising anticancer activity in human breast cancer cells. PDC/miRNA polyplexes show excellent ability to inhibit migration of cancer cells. Overall, this study supports the use of PDC as a promising polymeric drug platform for use in combination anti-metastatic and anticancer miRNA therapeutic strategies.

Indexed as

Breast NeoplasmsCell Line, TumorCell MovementCell ProliferationCell SurvivalChloroquineEndocytosisEndosomesFemaleGenetic VectorsHumansMethacrylatesMicroRNAsPolymersTransfection2-(dimethylamino)ethyl methacrylateChloroquineMethacrylatesMicroRNAsMIRN210 microRNA, humanPolymerschloroquineendosomal escapemiRNA deliverypolymeric drugpolyplex

Identifiers

PMID28776937
PMCPMC5997184
OpenAlexW2744356581

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.